Strategies for optimizing combinations of molecularly targeted anticancer agents.
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureImpact of fixed-dose combination of germacrone, curdione, and furanodiene on breast cancer cell proliferationThe pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsAdvances in drug delivery system for platinum agents based combination therapyA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyTargeting cancer with kinase inhibitorsStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewSmall molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathwaysApproaches to modernize the combination drug development paradigmCombination therapeutics in complex diseasesCombined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signaturesWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?Tumor burden talks in cancer treatment with PEGylated liposomal drugsTarget inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathwaysAn effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulaeChemogenomics and orthology-based design of antibiotic combination therapiesPortfolio Decisions in Early DevelopmentSynthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyModeling Tumor Clonal Evolution for Drug Combinations DesignMiniaturized pre-clinical cancer models as research and diagnostic tools.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesA Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesImproved network performance via antagonism: From synthetic rescues to multi-drug combinations.Nano-polypharmacy to treat tumors: coencapsulation of drug combinations using nanoparticle technology.Network target for screening synergistic drug combinations with application to traditional Chinese medicineDesign of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeAdvancing cancer drug discovery towards more agile development of targeted combination therapies.Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Nanocarriers for delivery of platinum anticancer drugs.Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activityComputational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancerFool's gold, lost treasures, and the randomized clinical trial.Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodiesClosed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm.Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach.
P2860
Q24289511-945E15D9-8C47-4984-9F10-95B0E35F0C12Q24564024-65515EB7-985D-430E-949C-5DC568330534Q24598351-B83A324D-0544-492F-8A49-C77EB9C11FD5Q26740374-3AF844F4-B881-4893-A741-2F06822F35D4Q26771390-48785446-E79C-476F-9879-2F620D20D88DQ26824462-E80F8B05-136F-4639-9CA0-B89A3CD8114AQ26865765-6B917A32-295F-4234-99EA-8E8C6D81B65AQ27008867-6D0F6E40-D5E9-429E-B348-C12B3EF56834Q27317155-CFD378EA-6A3C-445A-94D9-63A9B501B329Q28072074-CD14AA84-7720-4ECF-90DA-A746BAFB30B4Q28076891-94846CED-F4CE-4930-8454-0C7CA9393A27Q28484238-4071B52E-0BA4-4248-A2DE-3C2AF11B270AQ28485360-ED20FB5A-9EF7-4178-BBB0-AC4E21C2ECD1Q28487925-40FF6592-A7F4-4126-82EC-C07058F1268FQ28533401-F9B70920-36E6-4691-BAE2-3D30E61A9A49Q28535072-6E1AED78-3782-4C0B-88C0-661B4E59528FQ28817589-2097A61A-BD16-40ED-89F8-5C9B30A891B6Q29999056-482964FB-09A5-47C0-9B26-7B82ACE6B3F8Q30416651-3A520258-F213-42D3-AAAC-7B1E6BF85298Q33502835-7EF90370-4264-4460-9C2A-893C2B7AB1CBQ33590430-6F5112DF-24FB-417B-A832-D04C064C6C5AQ33605145-7E79BC0D-10B7-4DC3-9AD4-348702184C6FQ33730375-2D475157-7FB1-4DF7-B694-9AAAD48416A7Q33735754-9F2FF821-D5AC-4EC3-85A5-E005617FB14FQ33739810-373D764E-42AC-4F1E-9B1E-93CC76A63A46Q33870663-5D6DABA1-DAC5-44E0-9DD5-B15A4F196D1AQ33937467-498DA7D6-DCBF-4AAA-94F9-D07B6DC86D1BQ34056295-A62D6838-6D12-4678-B544-A60573077191Q34100574-0978EF64-47C9-41B8-A454-CFCAF6142AB0Q34265716-67C5EA91-D2E7-4FA0-8E33-0AE65905502FQ34338695-1A23B305-7023-4EAD-9FE9-975623228052Q34554594-8C586914-C8A8-4345-BC87-EE5A14826FD7Q34618624-B7C9AA45-BF35-43DA-B17B-7359FDCD4AD7Q34669260-5DB78910-5464-41F4-8358-15477A29ACB2Q34757809-DE0CA3DE-06EA-486C-93C0-DA55BF312231Q34763799-B1A2479E-0DC6-4EEC-B2F5-F3F589F1F5F3Q34787415-D9E4AD2E-0FCF-4E7A-A0D8-E684961DBF4EQ34948729-374C67A8-BF36-43FB-AA92-14CEEB70FBADQ35084128-B173CF32-6D00-4CB6-8561-AA41DBC34872Q35229098-48293F45-099D-43E3-8F02-783D5716AE68
P2860
Strategies for optimizing combinations of molecularly targeted anticancer agents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@ast
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@en
type
label
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@ast
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@en
prefLabel
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@ast
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@en
P356
P1476
Strategies for optimizing combinations of molecularly targeted anticancer agents.
@en
P2093
Helen X Chen
Janet E Dancey
P2888
P304
P356
10.1038/NRD2089
P577
2006-08-01T00:00:00Z